How To Treat Amd Dry Wet And New Options?

Age-related macular degeneration, or AMD, is a leading cause of vision loss in adults over 50. Treatment depends entirely on which form you have. Dry AMD has no cure approved by the FDA, though specific supplement formulas and one newer drug can slow its progression in certain people. Wet AMD is treated with injections into the eye that can preserve and sometimes improve vision. Several new options have entered the picture in recent years.

What Is the Difference Between Dry and Wet AMD?

The two forms of AMD damage the same part of the eye but in different ways. The macula is the small central area of the retina responsible for sharp, straight-ahead vision. It is what you use to read, drive, and recognize faces.

In dry AMD, which accounts for roughly 85 to 90 percent of all cases, cells in the macula gradually break down. Yellow deposits called drusen build up beneath the retina. Vision loss tends to be slow and progressive. An advanced stage called geographic atrophy involves the death of retinal pigment epithelium cells and the light-sensing photoreceptors above them.

Wet AMD, also called neovascular AMD, is less common but far more destructive. Abnormal blood vessels grow beneath the retina and leak fluid or blood. This can distort vision within days to weeks. Wet AMD can develop in someone who already has dry AMD, and it can progress rapidly without treatment.

Both conditions affect central vision while usually leaving peripheral vision intact. That is why AMD rarely causes total blindness but can make reading, driving, and face recognition very difficult.

How To Treat AMD Dry, Wet, and New Options

Treatment falls into two distinct tracks. Dry AMD care focuses on slowing progression and managing risk. Wet AMD care focuses on stopping the leaking vessels quickly.

Dry AMD treatment

No FDA-approved treatment can reverse dry AMD. Two approaches have evidence behind them for slowing progression in specific groups.

The first is a specific high-dose supplement formula studied in the Age-Related Eye Disease Study, known as AREDS2. It contains vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper. Research found this formula reduced the risk of progression to advanced AMD in people who already had intermediate dry AMD or advanced AMD in one eye. It did not prevent AMD from developing in the first place, and it did not help people with early-stage disease. In other words, it is not a general vision supplement. It is targeted at a specific disease stage.

The second is a drug called pegcetacoplan, given as an injection into the eye. It is approved for geographic atrophy, the advanced form of dry AMD. Clinical trials showed it can slow the growth of atrophy, though the effect on vision itself has been modest and the drug carries a risk of converting dry AMD to wet AMD. Some retinal specialists recommend it for certain patients; others are cautious. This is an area where practice varies.

For everyone with dry AMD, the most consistent advice is to stop smoking, control blood pressure and cholesterol, and eat a diet rich in leafy greens and colorful vegetables. These steps support general health and are associated with slower AMD progression, though they are not a treatment in the strict sense.

Wet AMD treatment

Wet AMD is treated with anti-VEGF injections. VEGF is a protein that signals new blood vessels to grow and leak. Blocking it can dry up the fluid and stabilize vision.

Several drugs are used, including ranibizumab, aflibercept, and bevacizumab. Bevacizumab is used off-label for the eye, meaning it was approved for cancer but is widely and effectively used in ophthalmology. Large comparative trials found the main drugs perform similarly for most patients.

Injections are typically given monthly at first, then extended based on how the eye responds. Some patients need treatment every four weeks indefinitely. Newer formulations allow longer intervals for some people, which reduces the number of visits.

Anti-VEGF treatment does not cure wet AMD. It controls it. Stopping treatment usually leads to rapid vision loss, so ongoing monitoring is essential.

Newer options

Two developments have changed wet AMD care in recent years.

The first is longer-acting injectable drugs. Faricimab and a higher-dose form of aflibercept can, for some patients, be given every 8 to 16 weeks instead of every 4. This is not a cure and not right for everyone, but it can reduce the burden of monthly appointments.

The second is a port delivery system, an implant surgically placed in the eye that releases ranibizumab continuously over months. It is approved for wet AMD and refilled in a clinic. It suits some patients who struggle with frequent injections, though it requires a surgical procedure and carries its own risks.

Researchers are also studying gene therapy and oral medications for wet AMD, but these remain experimental. No large human trials have confirmed they work better than current injections.

Why Early Treatment Matters So Much

Wet AMD can cause permanent damage within weeks. Once photoreceptors die, no treatment brings them back. This is why any sudden change in central vision — straight lines looking wavy, a dark spot appearing, or rapid blurring — needs prompt evaluation.

A simple home test using an Amsler grid can help people with dry AMD notice conversion to wet AMD early. The grid is a square of straight lines with a dot in the center. If lines appear wavy or missing, that is a warning sign. It is not a diagnosis, but it is a reason to call an eye doctor quickly.

Dry AMD usually progresses over years, so the urgency is different. Still, regular monitoring matters because dry AMD can turn into wet AMD at any point.

What About Lifestyle and Prevention?

No lifestyle change has been proven to reverse AMD. Some habits are linked to lower risk or slower progression.

• Not smoking is the single most consistent factor linked to lower AMD risk.
• Eating leafy greens, fish, and a Mediterranean-style diet is associated with slower progression in some studies.
• Managing blood pressure and cholesterol supports eye health and general health.
• Wearing sunglasses may reduce UV exposure to the retina, though the evidence for AMD prevention is not strong.
• Regular eye exams allow early detection, which matters most for the wet form.

One clarification worth making: AREDS2 supplements are not a general-purpose eye vitamin. Taking them without intermediate AMD does not appear to prevent the disease, and high-dose zinc and vitamin E carry their own considerations. Anyone considering them should talk with an eye care professional first.

Can AMD Be Cured?

No. Neither dry nor wet AMD has a cure. Wet AMD can often be controlled well enough to preserve useful vision, especially when treated early. Dry AMD treatment aims to slow progression rather than stop or reverse it.

The outlook has improved meaningfully over the past two decades. Before anti-VEGF drugs, most people with wet AMD lost central vision within two years. Today, many retain reading vision with ongoing treatment. That is a real change, even though it is not a cure.

For advanced vision loss, low-vision rehabilitation, magnifiers, and assistive technology can help people maintain independence. These tools do not treat the disease, but they improve daily function.

What Should You Ask Your Eye Doctor?

If you have been diagnosed with AMD, a few questions can clarify your situation.

• Which form do I have, dry or wet?
• If dry, what stage am I at, and would AREDS2 supplements or pegcetacoplan apply to me?
• If wet, which injection drug is recommended, and how often will I need treatment?
• What warning signs should make me call right away?
• Are there newer options, like longer-interval drugs or an implant, that fit my case?

AMD care is not one-size-fits-all. The right plan depends on the form, the stage, how the eye responds, and other health factors. Ask for clear answers and expect them.